Trials / Terminated
TerminatedNCT01755871
Long-term Effect of Fingolimod on Circulating Immunocompetent Mononuclear Cells in Patients With Multiple Sclerosis
The Long-term Effect of Fingolimod on Circulating Immunocompetent Mononuclear Cells in Patients With Multiple Sclerosis
- Status
- Terminated
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- Heinrich-Heine University, Duesseldorf · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to explore immunomodulatory and immunosuppressive mechanisms of action of fingolimod in patients with Relapsing remitting multiple Sclerosis to collect data on biomarkers after initiation of fingolimod treatment.
Detailed description
After treatment with fingolimod the blood of the patients will be collected at different time points to examine the changes of T cells, B cells and biomarkers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fingolimod | 0,5mg Fingolimod once a day |
Timeline
- Start date
- 2013-01-01
- Primary completion
- 2016-01-01
- Completion
- 2016-02-01
- First posted
- 2012-12-24
- Last updated
- 2016-06-09
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT01755871. Inclusion in this directory is not an endorsement.